• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ranbaxy Laboratories Limited (500359) - Financial and Strategic SWOT Analysis Review Product Image

Ranbaxy Laboratories Limited (500359) - Financial and Strategic SWOT Analysis Review

  • Published: May 2011
  • Region: Global
  • 38 pages
  • GlobalData

FEATURED COMPANIES

  • Abbott India Limited
  • IPCA Laboratories Limited
  • Novartis India Limited
  • MORE

Ranbaxy Laboratories Limited (500359) - Financial and Strategic SWOT Analysis Review

Summary

Ranbaxy Laboratories Limited (Ranbaxy) is engaged in the manufacturing, marketing and distribution of pharmaceutical ingredients. The product portfolio of the company includes Simvastatin, CoAmoxyclav, inter alia, Amoxycillin, Ciprofloxacin, Isotretinon and Cephalexin. The major markets of the company’s products include India, the US, Europe, Russia, South Africa and Brazil. The company’s manufacturing facilities are located in various nations, namely, China, India, Brazil, Malaysia, Nigeria, Ireland, Japan, Romania, South Africa, Vietnam and the US. It serves customers in over 125 countries worldwide. Ranbaxy holds a research and development facility in Gurgaon, New Delhi, India. Ranbaxy is headquartered at Gurgaon in Haryana, India.

Ranbaxy Laboratories Limited Key Recent Developments…

Jan 31, 2011: Ranbaxy, Government Of Yaroslavl Region, Russia Sign MoU In Healthcare And Medical Science
Sep 01, 2010: Ranbaxy Opens New Manufacturing Facility In South Africa
Aug 12, 2010: Ranbaxy Announces Senior Management Changes
Jul 21, 2010: Daiichi READ MORE >



List of Tables
List of Figures
Section 1 - About the Company
Ranbaxy Laboratories Limited - Key Facts
Ranbaxy Laboratories Limited - Key Employees
Ranbaxy Laboratories Limited - Key Employee Biographies
Ranbaxy Laboratories Limited - Major Products and Services
Ranbaxy Laboratories Limited - Pharmaceutical Pipeline Products Data
Ranbaxy Laboratories Limited, Pipeline Products by Therapy Area
Ranbaxy Laboratories Limited, Pipeline Products by Development Phase
Ranbaxy Laboratories Limited - History
Ranbaxy Laboratories Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Ranbaxy Laboratories Limited - Business Description
Ranbaxy Laboratories Limited - SWOT Analysis
SWOT Analysis - Overview
Ranbaxy Laboratories Limited - Strengths
Strength - Strong Research and Development
Strength - Growth Prospects
Strength - Extensive Product Portfolio
Ranbaxy Laboratories Limited - Weaknesses
Weakness - Increased Operational Cost
Weakness - Involvement in Legal Actions
Ranbaxy Laboratories Limited - Opportunities
Opportunity - Emerging Markets
Opportunity - Changing Demographics
Ranbaxy Laboratories Limited - Threats
Threat - Intense Competition
Threat - Product Liability Claims
Threat - Government Regulations
Ranbaxy Laboratories Limited - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ranbaxy Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Ranbaxy Laboratories Limited, Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Ranbaxy Laboratories Limited, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jan 31, 2011: Ranbaxy, Government Of Yaroslavl Region, Russia Sign MoU In Healthcare And Medical Science
Sep 01, 2010: Ranbaxy Opens New Manufacturing Facility In South Africa
Aug 12, 2010: Ranbaxy Announces Senior Management Changes
Jul 21, 2010: Daiichi Sankyo To Leverage Ranbaxy’s Network To Market Tavanic In Romania And South Africa
Jul 02, 2010: Daiichi Sankyo And Ranbaxy To Integrate New Drug Research And Development System
Jun 08, 2010: Ranbaxy Launches Generic Atorvastatin, ‘lipogen’, A Cholesterol-Reducing Medication In South Africa
May 21, 2010: Ranbaxy Launches Atorvastatin, Cholesterol-Reducing Medication Into The Canadian Healthcare System
Mar 29, 2010: Ranbaxy To Develop Biosimilar Therapeutic Protein In Collaboration With Pfenex
Mar 29, 2010: Syncom Healthcare Plans For New Contract Manufacturing Agreements
Mar 29, 2010: Ranbaxy Partners With Pfenex For Development Of Biosimilar Therapeutic Protein
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

Ankur Drugs and Pharma Ltd.
GlaxoSmithKline Pharmaceuticals Limited
Abbott India Limited
Dr. Reddy's Laboratories Limited
Novartis India Limited
IPCA Laboratories Limited
Sun Pharmaceutical Industries Limited
Morepen Laboratories Limited

Note: Product cover images may vary from those shown

RELATED PRODUCTS